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Comparison of Methods for Estimating
Therapy Effects by Indirect Comparisons:
A Simulation Study
Dorothea Weber, Katrin Jensen, and Meinhard Kieser
Objective. In evidence synthesis, therapeutic options have to be compared despite the lack of head-to-head trials.
Indirect comparisons are then widely used, although little is known about their performance in situations where
cross-trial differences or effect modification are present. Methods. We contrast the matching adjusted indirect com-
parison (MAIC), simulated treatment comparison (STC), and the method of Bucher using a simulation study. The
different methods are evaluated according to their power and type I error rate as well as with respect to the coverage,
bias, and the root mean squared error (RMSE) of the effect estimate for practically relevant scenarios using binary
and time-to-event endpoints. In addition, we investigate how the power planned for the head-to-head trials influences
the actual power of the indirect comparison. Results. Indirect comparisons are considerably underpowered. None of
the methods had substantially superior performance. In situations without cross-trial differences and effect modifica-
tion, MAIC and Bucher led to similar results, while Bucher has the advantage of preserving the within-study rando-
mization. MAIC and STC could enhance power in some scenarios but at the cost of a potential type I error
inflation. Adjusting MAIC and STC for confounders that did not modify the effect led to higher bias and RMSE.
Conclusion. The choice of effect modifiers in MAIC and STC influences the precision of the indirect comparison.
Therefore, a careful selection of effect modifiers is warranted. In addition, missed differences between trials may lead
to low power and partly high bias for all considered methods, and thus, results of indirect comparisons should be
interpreted with caution.
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In medical practice, physicians frequently face situations
where various therapy options exist. Ideally, all these
therapies were previously compared in several clinical
trials. However, often only 2-arm trials were conducted
comparing just a subset of all possible therapies. In situa-
tions where a head-to-head comparison is missing, the
question arises whether and how reliable and valid con-
clusions on the choice of the best treatment option can
be drawn. In the last years, so-called indirect compari-
sons have attracted considerable attention.1,2 Especially
in the field of health technology assessments (HTAs),
indirect comparisons are of increasing interest, because
valid comparator treatments are defined for early benefit
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assessment, and pharmaceutical industry frequently lacks
for direct comparisons with this valid comparator.3
Simply merging the results from different trials to get an
estimate for the missing comparison of interest can lead
to severe bias due to cross-trial differences. For example,
worse baseline disease status in one of the trials may sug-
gest that a treatment is more or less effective.4 Therefore,
powerful methods for indirect comparisons are needed.
In case individual patient data (IPD) are available,
using these data may increase the reliability of the results
and may reduce the uncertainty in treatment effects com-
pared to situations where only aggregated data are avail-
able. We consider the situation where 2 treatments, A
and C, are compared to a common comparator B in
head-to-head trials. IPD are available for the trial A v. B
(AB), whereas for the trial C v. B (CB), only aggregated
data (AgD) are accessible from published results (see
Figure 1). We are interested to find a treatment effect
between A and C (AC) under the assumption that the
population of interest is given by the population consid-
ered in the CB trial. The method of Bucher,5 the
matching-adjusted indirect comparison (MAIC),4 and
the simulated treatment comparison (STC)6 address this
setting of an anchored indirect comparison. In early ben-
efit assessment, the acceptance of population-adjusted
indirect comparisons with a common comparator differs
between health regulatory authorities. For example, the
Institute for Quality and Efficiency in Healthcare
(IQWiG) in Germany approves indirect comparisons by
the method of Bucher and the MAIC, but they are fre-
quently rejected due to the lack of suitable data.7,8 The
National Institute for Health and Care Excellence
(NICE) accepts indirect comparisons conducted by the
method of Bucher as well as the MAIC and STC in case
there is evidence that the population adjustment pro-
duces less biased effect estimates.9
Little is known about how indirect comparisons per-
form in situations where interactions are present,
assumptions of the methods for indirect comparisons are
violated such as differences in the patient population, or
when cross-trial differences exist, like different confoun-
der adjustment of regression models for evaluating the
treatment effect. To examine those situations, simulation
studies covering a variety of practically relevant scenar-
ios are needed.10–13
Our simulation study has 2 aims. First, we investigate
the method of Bucher, the MAIC, and the STC in a wide
range of practically relevant scenarios where assump-
tions are violated and cross-trial differences exist. Those
scenarios are of particular interest for benefit assessment
because they are likely to be rejected by health regulatory
authorities. The method of Bucher is applicable even if
only aggregated data are available for both trials AB
and CB. A problem arising for the method of Bucher
may be the insufficient comparability of studies according
to important effect modifiers. MAIC and STC address this
problem of differing patient populations by a matching
procedure. However, individual patient data need to be
available for one trial and aggregated data for the other
trial to conduct an indirect comparison by MAIC or STC.
Published results of simulation studies in the context of
indirect comparisons show unsatisfactory results, especially
according to power, which means to detect a treatment dif-
ference by the indirect comparison.3,14 Snapinn and Jiang15
showed that the sample size needed for an indirect compar-
ison is always higher than for the underlying direct com-
parison. Therefore, as the second aim of this simulation
study, we investigate the influence of the power provided
by the sample size calculation for the head-to-head trials
on the power of the indirect comparison.
Methods
The most commonly applied methods to conduct indirect
comparisons are the method of Bucher, the MAIC, and
the STC. The situation that can be addressed includes 1
study for each used comparison, which means in Figure
1, 1 study for the comparison A v. B and 1 study for C v.
B. Even if only the treatment effects and their corre-
sponding variances for the 2 studies are available, the
method of Bucher can be applied. These treatment effects
can either be adjusted (if available) or unadjusted. IPD
are not required to conduct an indirect comparison. The
treatment effects are calculated for each trial separately
taking into consideration the randomization within the
trial. Hence, the method of Bucher preserves the within-
study randomization. A common comparator is needed
for calculating an indirect comparison (in Figure 1 treat-
ment B is the common comparator of the trials). The
assumptions for applying the method of Bucher are
shared effect modifiers and comparable study popula-
tions for important effect modifiers. Then, the effect esti-
mate d (log odds ratio for binary data, log hazard ratio
for time-to-event data) for the indirect comparison AC is
given by
dAC = dAB  dCB, ð1Þ
with dAB the effect estimate of the trial AB and dCB
accordingly. The variance of dAC is given by
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Var(dAC)=Var(dAB)+Var(dCB):
Without loss of generality, we assume IPD are available
for the comparison AB, and only AgD are given for the
trial comparing CB.
The MAIC approach needs IPD for at least 1 trial,
because the aim is to match the IPD to the AgD of the
other trial. The matching procedure selects a weight for
each patient to reach similarity in the summary measures
of the baseline characteristics of the IPD and AgD trial
and follows the idea of propensity score matching. The
odds between being a patient in trial AB v. trial CB pro-
vides the weights for balancing the populations. Since
IPD of baseline characteristics are available for only one
of the trials, the maximum likelihood method cannot be
applied. Instead, the method of moments addresses this
setting. The IPD is centered according to the aggregated
data xCB including the means and proportions, respec-
tively, of all matching baseline characteristics.
The weights are optimized using the Broyden-Fletcher-
Goldfarb-Shanno (BFGS) algorithm.16 The matching
procedure can be based on means and proportions as well
as on higher-order moments. For the sake of simplicity,
only means and proportions were used within this simula-
tion study. The assigned weight estimate v̂i is used in the
direct comparison AB to obtain the weighted effect estimate
d
weighted
AB . At last, the method of Bucher uses the weighted
effect estimate dweightedAB of the MAIC and the effect estimate
of the trial CB dCB for calculation of the effect estimate dAC
of the indirect comparison following equation (1). For more
detailed information about these methods, see Bucher et al.5
and Signorovitch et al.4
For the MAIC, the effective sample size (ESS)10 is cal-
culated to measure the differences in baseline characteris-
tics between the trials. The set of estimated weights v
contains information about these differences. The ESS is
calculated as follows:
neffective =
P
t =A,B
PNt(AB)
i= 1 v̂it
 2
P
t =A,B
PNt(AB)
i= 1 v̂
2
it
,
where t =A,B, denotes the treatment arms of the trial
AB and Nt(AB) the sample size of treatment arm t.
The STC introduced by Ishak et al.6 is based on a
regression model for the IPD, which is substituted in mean
covariate values. This substitution is done by including
covariate adjustment that centers all effect modifiers by
the mean values of the aggregated data. The centered
treatment effect dcenteredAB denotes the regression coefficient
of the treatment covariate. Then an indirect comparison is
conducted using the effect estimates dcenteredAB and dCB to
calculate the indirect treatment effect dAC. To supply
unbiased estimates, the regression model needs to be speci-
fied correctly. Ishak et al.6 propose to simulate the missing
arm, but we do not follow this suggestion as it introduces
additional variation. Instead, we proceed by substituting
in mean covariate values directly.9 More details are pro-
vided by Ishak et al.6 and Phillippo et al.9
Simulation Study
We perform a simulation study for a wide range of prac-
tically relevant scenarios to investigate the method of
Bucher, MAIC, and STC for indirect comparisons for
time-to-event and binary endpoints. We assess and com-
pare the statistical properties of the methods, including
bias in the estimated therapy effects, root mean squared
error (RMSE), coverage, type I error rates, and power.
We performed 10,000 simulation runs for each scenario.
For the method of Bucher, we assume that there are no
differences between trials AB and CB with respect to
effect modifiers. For the underlying indirect compari-
sons, nevertheless, this assumption needs to be evaluated
for each situation in practice. All simulations were done
with the statistical software R version 3.3.3.17
Data Simulation Procedure
The simulation setting included 2 studies, one comparing
treatment A v. B and another study comparing treatment
C v. B. A study comparing A v. C was assumed to be una-
vailable (Figure 1). The true treatment effects of treat-
ments AB, BC, and AC are expressed on the log hazard
ratio (HR) scale for a time-to-event setting or the log odds
ratio (OR) scale for a binary endpoint, respectively.
Figure 1 Indirect comparison. The plot shows the situation of
the indirect comparison A v. C considered in this simulation
study. To illustrate that cross-trial differences may exist,
treatment B is described as B1 for the individual patient data
(IPD) trial and B2 for the aggregated data (AgD) trial.
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The data-generating process includes 1 continuous and
3 binary variables, and covariances between the variables
were considered to include correlations between the vari-
ables (Table 1). In the following, similar populations
means that data for the trials AB and CB follow the same
distribution, and the term different corresponds to diver-
gence in the distribution parameters. For generating the
time-to-event endpoint, the event time and the censoring
time are sampled from a Weibull distribution (levent =
0:0002, vevent = 1:8, lcensoring = 0:00012, vcensoring = 2,
max: time= 100). The endpoint is generated by a Cox
proportional hazard model from those times and vari-
ables. In addition, the binary endpoint is generated by a
logistic regression model incorporating the variables as
covariates (‘‘confounders’’). The outcome generation
model with the link function g() looks as follows:
g yið Þ=b0 +btrxtr, i +bb1xb1, i +bb2xb2, i
+bb3xb3, i +bcxc, i
Table 2 contains the values for log HR and log OR of
the confounders in the models with respect to the
assumed treatment effect (see Table 3). Furthermore,
some simulation scenarios cover an interaction term
between a binary variable and the treatment. This vari-
able is then called an effect modifier. The following
equation shows the inclusion of the interaction between
binary variable 2 (b 2) and treatment in the outcome gen-
eration model:
g yið Þ=b0 +btrxtr, i +btrb1xtr, i  xb1, i +bb1xb1, i
+bb2xb2, i +bb3xb3, i +bcxc, i
In addition, Table 2 contains the corresponding log
HR and log OR. If the interaction term is included in
only one of the trials, the shared effect modifier assump-
tion is violated.
We limit the simulation study to these described clini-
cally inspired data because we do not aim to examine the
influence of the number or distributions of patient char-
acteristics itself but rather the violation of assumptions
and occurrence of cross-trial differences.
The true effect size of the trial AC is simulated as
high, medium, low, or no effect, with the exact values
given in Table 3. This classification of treatment effects
is traced back to the benefit assessment of new drugs,
which aims to test whether a new drug results in an
added benefit compared to the current standard of
practice. Effect sizes in terms of log HRs for time-to-
event endpoints are classified according to Skipka
et al.18 For the ease of comparability, the log ORs for
binary endpoints are set to similar values. Sample size
calculations are based on established formulas19,20 (the
effects given in Table 3), a 5% type I error rate, and
80% power. The target population for the indirect
comparison is given by the CB population.
Table 1 Patient Characteristics and Covariance Matrices Used for the Data-Generating Process for the 2 Trials
Population
Similar Different
Variable AB/CB AB1 CB2
Continuous, mean (SD) 55 (15) 55 (15) 65 (10)
Binary1 (= 1), % 0.7 0.7 0.5
Binary2 (= 1), % 0.8 0.8 0.6
Binary3 (= 1), % 0.4 0.4 0.45
Covariance 225 0:25 0:05 0:01
0:25 0:2 0:01 0
0:05 0:01 0:15 0:05
0:01 0 0:05 0:1
0
BB@
1
CCA
225 0:25 0:05 0:01
0:25 0:2 0:01 0
0:05 0:01 0:15 0:05
0:01 0 0:05 0:1
0
BB@
1
CCA
100 0 0:05 0:01
0 0:25 0:01 0
0:05 0:01 0:1 0:05
0:01 0 0:05 0:15
0
BB@
1
CCA
Table 2 Regression Coefficients in Terms of Log Hazard
Ratios (HRs) for Cox Proportional Hazards Models and Log
Odds Ratios (ORs) for Logistic Regression Models Considered
for Simulation of Outcomes
Variable
Time-to-Event
Log HR
Binary
Log OR
Continuous (c) 20.0051 0.06
Binary1 (b1 = 1) 20.2 21.76
Binary2 (b2 = 1) 0.18 1.26
Binary3 (b3 = 1) 20.14 20.2
Interaction
Treatment and binary1 (= 1) 0.02 0.04
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Evaluation Measures
The performance of the 3 approaches is evaluated by the
bias of the effect estimate (i.e., the difference to the true
treatment effect), the RMSE, the power, the actual type
I error rate, and the 2-sided 95% confidence interval
(CI) coverage, where the CI for the effect estimate in the
regression model relies on a normal approximation. The
power is assessed by the proportion of simulation runs
where 0 (no effect) is not included in the 2-sided 95% CI
of the effect estimate when in fact an effect exists. The
power is calculated for the categories high, medium, and
low effect. If there is no effect, we are interested in the
type I error rate, which is based on the proportion of
simulation runs where again 0 (no effect) is not covered
by the 2-sided 95% CI of the effect estimate for the indi-
rect comparison. The aim is to minimize bias, RMSE,
and inflation of the type I error rate, whereas power
ought to reach high values and the coverage should be
around 95%. All evaluation measures are calculated for
the indirect comparison AC and correspond to the pri-
mary treatment effect.
The Simulation Scenarios
We analyze indirect comparisons for a binary and a time-
to-event endpoint. In Table 4, the simulation scenarios
are depicted. They are characterized by the following 4
aspects:
1. similar or different distributions of patient charac-
teristics (proportions of categorical variables, mean,
and variance of continuous variables substantially
differ, and the cutoff between similar and different
depends on the variable and the objective of the
comparison),
2. inclusion of an effect modification (interaction term
between a binary variable and treatment),
3. similar or different confounders, and
4. differences in the presence of the interaction.
In addition, for the method of Bucher and MAIC, we
investigate the influence of the power planned for the
sample size calculation of the head-to-head trials (AB
and CB) on the power of the indirect comparison (AC).
The sample size calculations are based on established
formulas18,19 (the effects given in Table 3), a type I error
rate of 5%, and 80%, 90%, 95%, or 99% power. The
characteristics such as actual type I error rate, 95% CI
coverage, and bias of the effect estimate in the indirect
comparison are evaluated as well.
Results
This section is split according to the evaluation mea-
sures. For scenarios I to V, we focus on the situation
including individual studies that are planned for 80%
power and a 5% type I error rate. The effect estimates
are calculated by a logistic or a Cox regression model.
They can either be adjusted for effect modifiers and con-
founders or include the treatment group as a single cov-
ariate. Independent of the method for the indirect
comparison, we consider 3 settings for the calculation of
direct effect estimates: regression models in trials AB and
CB include all relevant effect modifiers and confounders,
regression models in trials AB and CB only include con-
founders (effect modifiers are treated as confounders;
note that in this case, STC is not considered, since its
concept is based on including effect modifiers), and the
Table 3 Values for Log Odds Ratios for Binary Endpoints
Including the Binary Event Rates (p1, p2) and Log Hazard
Ratios for Time-to-Event Endpoints for Different Effect
Classes
Time to Event AC AB CB
High 20.69 20.91 20.22
Moderate 20.22 20.44 20.22
Low 20.05 20.27 20.22
No 0 20.22 20.22
Binary AC AB (p1, p2) CB (p1, p2)
High 20.48 20.70 (0.45, 0.62) 20.22 (0.45, 0.51)
Moderate 20.23 20.45 (0.45, 0.56) 20.22 (0.45, 0.51)
Low 20.06 20.28 (0.45, 0.52) 20.22 (0.45, 0.51)
No 0 20.22 (0.45, 0.51) 20.22 (0.45, 0.51)
Table 4 Considered Simulation Scenarios
Population Confounders Interactions
Similar Different Similar Different AB CB
I x x
x x
II x x x x
x x x x
III x x x x
x x x x
IV x x x
x x x
V x x x
x x x
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regression model for trial CB is not adjusted for effect
modifiers or confounders. The aim is to investigate the
influence of this adjustment of the direct comparison to
the indirect comparison. In particular, for the method of
Bucher where usually AgD are used only, unadjusted
effect estimates might be available. The fifth paragraph
describes the influence of the planned power of the indi-
vidual trials on that of the indirect comparison. Within
each subsection, we describe the results for both end-
points. The detailed results of the different scenarios and
endpoints based on the described evaluation measures
can be found in Supplemental Tables S7 to S20. The
ESS is influenced by the differences in distributions of
variables considered in the MAIC procedure. Therefore,
it is independent of interactions or adjustment of regres-
sion models, and hence, the results are similar for all
considered scenarios (see Supplemental Tables S21–S25).
Power
In scenario I, no effect modification is present, but all
confounds are assumed to modify the effect, and MAIC
and Bucher show identical results for equal patient
groups. For those 2 methods, the power decreases for
lower treatment effects, whereas STC reaches higher val-
ues for smaller treatment effects. When characteristics
differ between trials, STC loses power. Scenario II
includes an interaction that makes MAIC achieve higher
power values when there are differences in the confoun-
der and effect modifier distributions for time-to-event
(TTE) endpoints. When adjusting MAIC only for the
effect modifiers, power is decreasing to a small amount.
STC produces comparable power values for equal and
different patient characteristic distributions. These power
values do not vary by a high amount between scenarios.
Only small differences are observed for STC when cen-
tering is considered for effect modifiers only. For binary
endpoints and present effect modification, MAIC results
in higher power values compared to Bucher and STC,
even when characteristics are equal. Furthermore, a
small increase is observed when MAIC adjusts for effect
modifiers only. In case confounder overlap differs (sce-
nario III), we observe similar results as for scenario II
for all 3 methods. In scenario IV, the power values are
relatively high and are comparable for both methods
when populations are similar. Adjusting MAIC for all
confounders leads to power loss compared to only
adjusting for effect modifiers when population distribu-
tions differ. In case the effect modification is not consid-
ered within the regression models for MAIC and Bucher,
we observe higher power values in scenarios where the
effect modification is present in both trials. When only
unadjusted effect estimates are available for CB (regres-
sion models are not adjusted for confounders and effect
modifiers) for TTE endpoints, power values decrease for
scenarios where effect modification is only present in
CB.
Type I Error Rate
In scenario I, Bucher and MAIC show type I error rates
around 5% for both endpoints. For STC, however, type
I error rate is around 5% only for binary endpoints, and
highly inflated type I error rates are observed for TTE
endpoints. Scenario II leads to type I error rates around
5% for all methods. If confounder overlap differs (sce-
nario III), the type I error rate remains as in scenario II.
However, if effect modification is only present in trial
CB, we observe a type I error rate inflation for Bucher
and MAIC as well. When populations are similar, the 2
methods perform equally, but in case of differences,
MAIC leads to lower type I error rates, which are still
highly inflated. In scenarios III and IV, STC leads to the
smallest type I error rates. For binary endpoints, MAIC
yields inflated type I error rates in all scenarios where
effect modification is present. When the effect modifica-
tion is not considered in the estimation of effects in direct
evidence, the type I error rate is controlled for scenarios
with effect modification in both trials.
Coverage
Given scenario I and binary endpoints, all methods show
comparable results. When an effect modifier is present
(scenario II), MAIC reaches coverage over 90%, whereas
Bucher leads to values lower than 90%. When perform-
ing STC, the coverage is below 50% for high and
medium treatment effects and increases for lower treat-
ment effects for TTE endpoints. When additionally con-
founders differ between trials in the binary case, MAIC
reaches higher coverage, whereas for TTE endpoints,
Bucher and MAIC show similar results. In scenarios IV
and V, we observe higher values for MAIC when popu-
lation distributions differ, but all values are below 85%.
Bias and RMSE
The bias and the RMSE are slightly higher for MAIC
when all confounders are considered in the matching step
of MAIC in scenario I for both endpoints. STC shows
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even higher bias and RMSE. When effect modifiers are
present and regression models are adjusted, Bucher and
MAIC give similar results for TTE endpoints, and STC
shows lower bias and RMSE. In the binary setting,
MAIC results in lower bias and RMSE compared to
Bucher and STC. In case confounder overlap differs (sce-
nario III), we observe only small differences to scenario
II. Scenarios IV and V show the lowest bias and RMSE
values for TTE endpoints, differences between Bucher
and MAIC are negligible for both endpoints, and for
STC, higher values are observed. When effect modifica-
tion is not considered in the regression models for effect
estimates of AB and CB, we even observe a slightly
smaller bias and RMSE. When CB is not adjusted for
any confounder, bias and RMSE increase for Bucher and
MAIC, whereas STC leads only to marginally higher bias
and to a lower RMSE compared to the other methods.
Effective Sample Size
The effective sample size for the MAIC procedure equals
the actual sample size for similar population distribu-
tions. When characteristics differ between trials and all
confounders are considered within MAIC, ESS results in
less than half of the actual sample size. Adjusting MAIC
solely for effect modifiers reduces the ESS by 15% to
20% only.
Influence of Power of Direct Comparisons
We varied the power used for the sample size calculation
for the trials AB and CB to investigate its influence on
the power of the indirect comparison. We analyze trials
powered at 80%, 90%, 95%, and 99%, including all pos-
sible power combinations. The power of the indirect
comparison increases with increasing power of the head-
to-head comparisons. However, even for trials powered
at 99%, the indirect comparison reaches a power of less
than 60% when all method assumptions are met
(Supplemental Table S26). Higher treatment effects in
the indirect comparison gain more power by increasing
the power in head-to-head trials. The results for a fixed
power of 80% in the AgD trial CB and increasing power
of the IPD trial AB are plotted in Figure 2. The type I
error rate remains at around 5% for all power scenarios.
The results for the bias of the effect estimate, RMSE,
and the coverage of the 95% CI are unchanged for all
power scenarios. These measures are already discussed
above.
Discussion
This simulation study observes that indirect comparisons
are highly underpowered in scenarios commonly met in
practice. Scenarios, where the assumptions of the meth-
ods (see Methods) hold true, perform better, but the per-
formance is far from being good in terms of power. This
observation is in line with other publications that include
simulation studies on indirect comparisons.3,14 Our results
also provide a rationale for why, as often in practice, the
application of indirect comparisons in early benefit assess-
ment leads to the conclusion that there is no additional
benefit.21 Even if there would be an actual benefit, it will
rarely be demonstrated by the indirect comparison due to
low power and wide confidence intervals.
The results show that there are situations where the
method of Bucher performs better than the matching
approaches and vice versa. Noticeable differences
between the matching methods are observed as well.
Deviations from the method assumptions result in biased
effect estimates. While MAIC results in less biased esti-
mates in some scenarios, STC shows higher bias and
RMSE in most of the scenarios. The superiority of the
MAIC over the method of Bucher is linked to the
Figure 2 Power of indirect comparison. The plot shows the
power of the indirect comparison (A v. C) depending on its
true effect. The power for the sample size calculation in direct
trial C v. B (aggregated data are available) is set to 80%, and
the power for A v. B (individual patient data is available) is
varied. Equal population distributions are considered, which
makes the results hold true for the method of Bucher and
matching adjusted indirect comparison (MAIC) because they
perform similarly in this scenario. IPD, individual patient data.
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presence of effect modification. However, there are also
situations when the MAIC leads to higher bias and less
power compared to the method of Bucher. This may be
explained by the 1-arm weighting when models are
already adjusted for all influencing confounders. Then,
the weighting may result in more biased effects for the
indirect comparison, which seems to be connected to the
MAIC adjusting for confounders that are not effect
modifiers. This situation, where models are adjusted for
all relevant confounders and effect modifiers, may not
always be given in practice, and moreover, this assump-
tion cannot be checked and increases bias and RMSE.
For STC, similar patterns are observed, and the perfor-
mance decreases when confounders are treated as effect
modifiers. When the set of confounders differs between
trials, the results remain comparable. However, when the
overlap of effect modifiers differs, type I error rate is
highly inflated, and in case of binary endpoints, bias and
RMSE are also higher as in other scenarios. Only STC
leads to results comparable to the situation where effect
modification is present in both trials. We observe situa-
tions where ignoring the effect modification leads to bet-
ter results. This may be since we evaluate the marginal
effect of the treatment and do not evaluate the interac-
tion term itself because it cannot be assessed by the mar-
ginal effect of the interaction.22 A limitation of the
MAIC and STC approach is the shift of the IPD towards
the AgD trial, which means that the AgD trial defines
the target population. Higher planned power in the sam-
ple size calculation of the direct trials increases the power
of the indirect comparison. Hence, investigators can
influence the power of a later indirect comparison by
planning the head-to-head trials on a higher power level.
One strength of our simulation study is the variety of
clinically relevant scenarios considered, including con-
founders, correlations, interactions (effect modification),
and adjustment of regression models, which are evalu-
ated and compared within this work. The sample size of
the simulated trials is based on a sample size calculation
for the assumed effects, making the results realistic and
transferable to real trials. The treatment effects are cho-
sen according to official recommendations for the classi-
fication of effects in benefit assessment, which makes the
scenarios practically relevant. Nevertheless, the following
limitations apply to the simulation study. We only con-
sidered 1 clinically inspired data set, and it is assumed
that the interaction terms have the same sign and that
the treatment effect modifiers are known. In addition,
the overlap of populations is good enough to expect
matching to work well. Note that this is mainly relevant
for variables considered in the matching procedure of
MAIC.
The MAIC in its original form can only be used con-
sidering 1 study per treatment comparison. However,
there are commonly at least 2 or even more studies per
treatment comparison available. Further research is
needed to develop, evaluate, and compare the method of
Bucher, MAIC, and STC using several studies per treat-
ment comparison and to expand these methods to net-
work settings. By using several studies, the decision is
based on a higher number of patients, which may lead to
more precise estimates and therefore to a higher power
for the indirect comparison.
A further limitation of this simulation study is that we
just compared the method of Bucher, MAIC, and STC
since they are widely used and accepted in the field of
HTA. Nevertheless, there are other methods available for
indirect comparisons (e.g., Droitcour et al.,23 Nie et al.,24
Jansen25) whose properties are currently not sufficiently
examined.3
Conclusion
Indirect comparisons allow for estimation of treatment
effects when studies comparing these therapies directly are
not available. An important step prior to conducting an
indirect comparison is the identification of possible under-
lying differences between the trials. Based on this knowl-
edge, the method for the indirect comparison should be
chosen carefully to avoid bias. In the case of similar patient
characteristics and adjusted effect estimates, the method of
Bucher has the advantage of preserving the within-study
randomization. However, in case of effect modification in
1 or both trials and differences with respect to effect modi-
fiers as well as adjustment of regression models, the MAIC
provides less biased effect estimates and higher coverage.
Matching variables in MAIC, as well as effect modifiers in
STC, need to be chosen carefully because including con-
founders, which do not modify the effect, influences the
precision of the indirect comparison. A summary of the
performance in the considered scenarios is given in Table 5
for TTE and in Table 6 for binary endpoints. Nevertheless,
results of indirect comparisons should be interpreted with
caution, and one should be aware of the potentially low
power if no treatment effect can be demonstrated in an
indirect comparison.
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